Splash Image
About Us

Investors & Partners

Translation through Collaboration

Built for Success

Northern Biologics was formed out of a unique academic drug discovery partnership, and collaboration is at the core of how we operate today.

We’ve combined a phage display discovery platform with an industry-experienced R&D team and a set of world-leading academic collaborators. Supported by blue chip investors and partners, this approach enables us to quickly access new targets, innovative preclinical models, patient samples, and the deepest thinking on molecular mechanisms in oncology and fibrosis.

Academia

Donnelly Centre for Cellular and Biomolecular Research

Donnelly Centre for Cellular and Biomolecular Research

Northern Biologics has established collaborations with top academic centers including:

  • University of Toronto’s Donnelly Centre
  • University Health Network’s Princess Margaret Centre
  • French Institute of Health and Medical Research (INSERM)

Our in-licenses of intellectual property from these institutions include a novel antibody generation platform and discovery stage antibody leads.

“The more people we can have working on targeted therapies, the more quickly we will be able to have a significant impact on patient outcomes,” Christopher Paige, Vice President of Research at University Health Network, has noted. “Patients expect us to be working in partnership, and Northern Biologics is a prime example of collaborative success.”

Investors

versant-ventures-logoNorthern Biologics is a privately held biotechnology company backed by Versant Ventures, a leading healthcare investment firm committed to helping exceptional entrepreneurs build the next generation of great healthcare companies.

Partners

celgeneWe have established an exclusive R&D collaboration with Celgene Corporation.

“Celgene’s collaboration with Northern Biologics represents a valued opportunity to support and advance the strong team and innovative projects Versant and the founders have assembled from the University of Toronto and Princess Margaret Cancer Centre” said Thomas Daniel, M.D., President, Global Research and Early Development at Celgene.